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Abstract
Purpose: To evaluate the efficacy of cytokine-induced killer (CIK) cell therapy in the treatment of hepatocellular
carcinoma.
Materials and methods: Randomized phase II and III trials on CIK cell-based therapy were identified by electronic
searches using a combination of “hepatocellular carcinoma” and “cytokine-induced killer cells”.
Results: The analysis showed significant survival benefit (one-year survival, p < 0.001; two-year survival, p < 0.001;
median overall survival, p < 0.001) in favor of CIK-based therapy. Comparison of CIK group versus non-CIK group
resulted in a significantly prolonged progression-free survival (PFS) (p < 0.01). A favored disease control rate (DCR)
and overall response rate (ORR) were also observed in patients receiving CIK cell therapy (p < 0.01). Meanwhile,
patients in the CIK group showed better quality of life (QoL), diminished HBV-DNA content and AFP level (p <
0.01). Comparing T-lymphocyte subsets in peripheral blood, the analysis showed the ratio of CD3+, CD4+, CD4+CD8
+ and CD3+CD4+ T cells significantly increased in the CIK group, compared with the non-CIK group (p < 0.01).
Conclusions: CIK cell therapy demonstrated a significant superiority in prolonging the median overall survival, PFS,
DCR, ORR and QoL of HCC patients. These results support further larger scale randomized controlled trials for HCC
patients with or without the combination of other therapeutic methods.
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Introduction
Hepatocellular carcinoma (HCC) is the third most com-
mon cancer globally, with a poor prognosis and limited
systemic treatment options [1]. In men, it is the fifth
most common cancer worldwide and the third-leading
cause of cancer-related death [2]. HCC is resistant to
conventional chemotherapy and is insensitive to radio-
therapy. Surgery, transcatheter arterial chemoemboliza-
tion (TACE) and radiofrequency ablation (RFA) are
considered as the main treatments for HCC today [3].
However, the recurrence rate is still high, and long-term
survival is unsatisfactory, as approximately 80% of
patients die within a year of diagnosis. After curative
resection or transplantation, tumor recurrence rate can
be as high as 25% per year. Although some centers have
reported excellent long-term results, survival after hepa-
tic resection or transplantation is as low as 50% at 3
years and 20%-30% at 5 years [4]. Therefore, finding
effective methods to strengthen treatment efficacy and
prevent recurrence is an important issue in HCC
therapy.
Cytokine-induced killer (CIK) cells, which are non-
major histocompatibility complex (MHC)-restricted
CD3+CD56+ T cells, take advantage of the body’s nat-
ural ability to eliminate tumor cells by stimulating and
restoring the immune system to recognize and kill
tumor cells [5]. Majority of CIK cells express T cell
receptors, and others express NK cell markers. CIK cells
are generated by incubating mononuclear cells from
peripheral blood, bone marrow or cord blood with var-
ious types of additions. Current protocols to
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differentiate CIK cells are based on a combination of
interferon (IFN)-g on day 1 of culture, followed by CD3
monoclonal antibody (CD3McAb), interleukin2 (IL2),
interleukin1 (ILl) 24 hours later [6,7]. CIK cells have
higher proliferation rate, cytolytic activities and non-
MHC-restricted killing of tumor cells in comparison
with lymphokine-activated killer cells (LAK cells) which
are essentially activated by natural killer (NK) cells [8,9].
Clinical studies indicated that autologous CIK cell
therapy could be used as an efficient adjuvant anticancer
immunotherapy to eradicate residual cancer cells, pre-
vent recurrence, improve progression-free survival (PFS)
rates, and promote the quality of life (QoL) for cancer
patients [10-14]. Therefore, we performed a systematic
review and meta-analysis of randomized controlled clini-
cal trials (RCTs) to assess the efficacy and tolerability of
CIK cells in the treatment of patients with HCC.
Materials and methods
Study design, search strategy, and eligibility criteria
Trials were identified by electronic searches in the
PubMed database, the Cochrane Central Registry of
Controlled Trials, the Wanfang Database, the China
Science and Technology Periodical Database, China
Journal Net, reference lists of published trials and rele-
vant review articles. The search strategy included the
medical subject headings of “hepatocellular carcinoma”,
“cytokine-induced killer cells” and free text searches. No
language limits were applied. Initial searches were per-
formed in August 2011, with updates in February 2012.
In addition, we contacted drug manufacturers, asked
experts in the field, and performed manual searches in
reference lists, conference proceedings of the American
Society of Clinical Oncology (ASCO) Annual Meetings
and the European Cancer Conference (ECCO). We
excluded abstracts that were never subsequently pub-
lished as full papers and studies on animals.
Data collection
We gathered information including authors’ names,
journal and year of publication, sample size per arm,
performance status (PS score), regimen used, median
age of patients, and information pertaining to study
design (whether the trial reported the mode of randomi-
zation, allocation concealment, description of withdra-
wals per arm, and blinding) for the trials included in the
study. Written informed consent was obtained from the
patient for publication of this report and any accompa-
nying images.
Definition of outcome measures
Overall survival (OS) and the PFS were the primary out-
come measure. OS was defined as the time from the
initiation of treatment until death from any cause. PFS
was defined as the time from the initiation of treatment
to the first observation of disease progression or death
from any cause. The secondary endpoints were the over-
all response rate (ORR) and disease control rate (DCR).
Toxicity was graded according to the NCI Common
Toxicity Criteria. QoL was assessed by the Karnofsky
performance status (KPS) [15].
Statistical analysis
The analysis was performed using a Review Manager
Version 5.0 (Nordic Cochran Centre, Copenhagen). We
defined a statistical test with a p value less than 0.05 as
significant. Odds ratio (OR) and 95% confidence interval
(CI) as relevant effect measures were estimated directly
or indirectly from the given data. Where they were not
provided, they were estimated indirectly from other
summary statistics or from the data extracted from pub-
lished Kaplan-Meier curves. To assess statistical hetero-
geneity among trials, the Cochran’s chi-square test (Q
test) was performed, with a predefined significance
threshold of 0.05. If the Q test was statistical significant
(p < 0.05), a random effects meta-analysis was per-
formed; otherwise, a fixed effect model was used. All
reported p values result from two-sided versions of the
respective tests. The revision of funnel plots did not
reveal any considerable publication bias.
Results
Selection of the trials
The electronic searches yielded two hundred eighty six
references. After title and abstract review, 252 publica-
tions were excluded for different reasons (25 for being
review articles, 119 for using animal models, 6 for being
case reports, 98 for being vitro experiments, 4 for being
nursing studies). The full texts of 34 articles were
selected as potentially relevant and retrieved for more
detailed assessment. We excluded a total of 21 studies
for the following reasons: 3 trials were excluded for
being phase I clinical trials, 18 trials were excluded for
being non-RCTs. The selection procedure of the clinical
trials is shown in Figure 1. As a result, 13 articles
reporting phase II and III clinical trials of CIK cell-
based therapy were selected for meta-analysis. These 13
eligible RCTs included a total of 1212 patients.
Characteristics of CIK cell-based therapy
Clinical data of these trials are listed in Table 1. CIK
therapy combined with TACE in four of the trials
[16-19], with TACE and RFA in other four of the trials
[20-23], with surgery alone in three trials [24-26], with
TACE alone or TACE and percutaneous ethanol injec-
tion (PEI) in other two trials [27,28] were evaluated.
IFN-g, CD3McAb, IL-1a and IL-2 were used in CIK cell
culture system in all of the analyzed trials.
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The CIK cells for all trials were prepared from periph-
eral blood. The number of CIK cells transfused into
patients in these studies ranged from 8.0 × 109 to 5.0 ×
1010 per course. The patient information from two
groups (CIK cell therapy and non-CIK cell therapy) of
the trials such as gender and CIK cell dose were ana-
lysed by c2 test. There was no statistically significant dif-
ference between groups (p > 0.05). Different article-
origin of the patient information in each group did not
interfere with the results of meta-analysis.
Survival
The analysis showed that significant survival benefit
(OS: OR = -20.01, 95% CI: -25.72 to -15.31, p < 0.001)
was observed in patients receiving CIK-based therapy.
The results of the pooled analysis showed that CIK arm
was associated with significantly improved one-year sur-
vival (OR = 0.25, 95% CI: 0.12 to 0.52, p < 0.001) and
two-year survival (OR = 0.17, 95% CI: 0.07 to 0.43, p <
0.001). However, there was no difference in half-year
survival comparing the CIK group versus non-CIK
group (77% in CIK group versus 67% in the non-CIK
group; OR = 0.43, 95% CI: 0.05 to 3.94, p = 0.45) (Fig-
ure 2).
Concerning PFS, treatment with CIK-combined ther-
apy was also associated with a significantly prolonged
half-year PFS (OR = 0.29, 95% CI: 0.16 to 0.52, p <
0.001) and one-year PFS (OR = 0.35, 95% CI: 0.22 to
0.53, p < 0.001) (Figure 3).
Response rate
The analysis of DCR and ORR also demonstrated favor-
able results for the CIK cell therapy arm (OR = 0.09,
95% CI: 0.04 to 0.25, p < 0.001 and OR = 0.21, 95% CI:
0.13 to 0.35, p < 0.001) (Figure 4).
In the subgroup analysis, a significantly prolonged
DCR (OR = 0.08, 95% CI: 0.02 to 0.40, p = 0.002) and
ORR (OR = 0.36, 95% CI: 0.17-0.72, p = 0.004) were
observed in the patients treated with CIK combined
TACE therapy compared with those treated with TACE
combined PEI therapy.
Toxicity, HBV-DNA content and plasma AFP
In most trials, slight fever and chills could be seen, and
the body temperature varied from 37.5°C to 39.0°C
within 24 hours after CIK cell transfusion. The overall
OR of 0.07 (95% CI: 0.01 to 0.53) demonstrated that the
incidence of fever in the CIK therapy group was signifi-
cantly higher than those in the non-CIK group (p =
0.01).
We classified QoL as “improvement”, “stability” or
“deterioration”, if KPS was higher than, equal to or
lower than pretreatment, respectively. The analysis
showed that TACE combined CIK therapy can improve
Figure 1 Flow diagram of the study selection process.
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HCC patients’ QoL, showing a better QoL (OR = 0.32,
95% CI: 0.16 to 0.64, p = 0.001) when compared with
non-CIK therapy. The HBV-DNA content in the analy-
sis was based on two HCC trials [21,22]. During one-
year follow-up, no patient HBV-DNA content was more
than 1 × 106 copy/ml in the CIK therapy group. Patients
in the CIK group had lower HBV-DNA content than
patients in the non-CIK group (OR = 27.5, 95% CI: 5.21
to 145.15, p < 0.01). (Table 2).
The AFP content in the analysis was based on three
HCC trials 23,26.27. Plasma AFP decreased more signifi-
cantly in the CIK group than in the non-CIK group (OR
= 0.20, 95% CI: 0.14 to 0.29, p < 0.001). Plasma AFP of
patients in the CIK group was more likely to drop to a
normal level, compared with the non-CIK group (OR =
0.20, 95% CI: 0.11 to 0.35, p < 0.001), the TACE alone
group (OR = 0.12, 95% CI: 0.05 to 0.26, p < 0.001) and
the PEI group (OR = 0.34, 95% CI: 0.16 to 0.72, p =
0.005) (Figure 5).
Comparison of T-lymphocyte subsets in peripheral blood
The analysis showed the ratio of CD3+, CD4+, CD4
+CD8+ and CD3+CD4+ T cells significantly increased in
the CIK group, compared with the non-CIK group,
which was reflected by a pooled OR of -0.79 for CD3+
cells (95% CI:-1.13 to -0.45, p < 0.001),-2.00 for CD4+
cells (95% CI:-2.7 to -1.3, p < 0.001), 0.04 for CD4+CD8
+ cells (95% CI: 0.03 to 0.05, p < 0.001), and -2.02 for
CD3+CD4+ cells (95% CI:-2.27 to -1.76, p < 0.001).
Furthermore, the percentage of CD8+ and CD3+CD8+ T
Table 1 Clinical information of the eligible trials for the meta-analysis
Trial No. of pts Regimens (per arm) No. of pts
(Male)
CIK Regimens Culture of CIK cell
Dong 2009 [24] 127 CIK (3 course) 41 (31) 1.0-2.0 × 1010 per course CM, IFN-g, CD3McAb, IL-1a, IL-2
CIK (6 course) 43 (32)
Surgery only 43 (34)
Weng 2008 [20] 85 TACE + RFA + CIK 45 (31) 1.0-1.5 × 1010 per course CM, IFN-g, CD3McAb, IL-1a, IL-2
TACE + RFA 40 (29)
Zhao 2006 [21] 64 TACE + RFA 31 (29) 1.1-1.5 × 1010 per course CM, IFN-g, CD3McAb, IL-1a, IL-2
TACE + RFA + CIK 33 (30)
Pan 2010 [22] 83 TACE + RFA + CIK 42 (37) > 1.0 × 1010 per course CM, IFN-g, CD3McAb, IL-1a, IL-2
TACE + RFA 41 (34)
Hao 2010 [19] 146 TACE 74 (64) 1.0-5.0 × 1010 per course SFM, IFN-g, CD3McAb, IL-1a, IL-2
TACE + CIK 72 (65)
Lu 2008 [25] 30 CIK 12 (UK) 1.6 × 1010 per course SFM, IFN-g, CD3McAb, IL-1a, IL-2
Surgery alone 18 (UK)
Zhang 2007 [16] 44 TACE 20 (UK) 8.0 × 109 per course CM, IFN-g, CD3McAb, IL-1a, IL-2
TACE + CIK 24(UK)
Guo 2007 [17] 61 TACE 31 (UK) 1.0-1.2 × 1010 per course CM, IFN-g, CD3McAb, IL-1a, IL-2
TACE + CIK 30 (UK)
Zhang 2006 [27] 144 TACE 30 (UK) 1.0-1.2 × 1010 per course CM, IFN-g, CD3McAb, IL-1a IL-2
TACE + CIK 16 (UK)
TACE + PEI 62 (UK)
TACE + PEI + CIK 36 (UK)
Shi 2007 [28] 252 TACE 134 (UK) 1.0-1.2 × 1010 per course CM, IFN-g, CD3McAb, IL-1a, IL-2
TACE + PEI 80 (UK)
TACE + CIK 38 (UK)
Hao 2006 [18] 67 TACE + CIK 21 (17) 1.0-5.0 × 1010 per course CM, IFN-g, CD3McAb, IL-1a, IL-2
TACE 46 (45)
Wan 2008 [23] 61 TACE + RFA 34 (23) 1.0 × 1010 per course CM, IFN-g, CD3McAb, IL-1a, IL-2
TACE + RFA + CIK 27 (18)
Yu 2009 [26] 50 TACE + CIK 25 (22) 1.0-1.2 × 1010 per course CM, IFN-g, CD3McAb, IL-1a, IL-2
Surgery alone 25 (23)
Note: UK unknown; pts patients; TACE transcatheter arterial chemoembolization; RFA radiofrequency ablation; PEI percutaneous ethanol injection; IL interleukin;
IFN-g Interferon-g; CM complete medium; SFM Serum-free culture medium
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cells significantly decreased in the CIK group compared
with the non-CIK group (95% CI: 2.43 to 3.67, p <
0.001; 95% CI:-2.1 to -1.56, p < 0.001; respectively)
(Table 3).
Discussion
According to research in recent years, HCC patients
have some immune dysfunctions, including those in
innate and adaptive immune responses [29]. It has been
reported that interferon therapy appeared to decrease
recurrence rate after resection of hepatitis C virus or
hepatitis B virus-related HCC in some randomized
controlled trials. Tumor immunological studies show
that cellular immunity of cancer patients is closely
related to the occurrence and development of cancers.
Cytokine immunotherapy not only has fewer side effects
but also can avoid tumor dysimmunity and specific tol-
erance of tumor antigen. With the rapid advance of
molecular biology technology, the application of immu-
notherapy combined with surgery or interventional ther-
apy is thought to be promising strategy of HCC
treatment.
Schmidt-Wolf et al. [5] first reported that CIK cells
had a strong anti-proliferative capacity and cytotoxicity
Figure 2 Comparison of 0.5-year, 1-year, and 2-year survival between non-CIK group and CIK group. OR, odds ratio; OS, overall survival.
non-CIK, non-CIK-containing therapy; CIK, CIK-containing therapy. The random effects meta-analysis model (Mantel-Haenszel method) was used
in this analysis. Each trial is represented by a square, the center of which gives the odds ratio for that trial. The size of the square is proportional
to the information in that trial. The ends of the horizontal bars denote a 95% CI. The black diamond gives the overall odds ratio for the
combined results of all trials. The center denotes the odds ratio, and the extremities denote the 95% CI.
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on tumor cells. Further studies have demonstrated that
CIK cells, which are lymphocytes induced by many cyto-
kines [30], have better anti-tumor effects compared with
LAK cells (lymphocytes activated by IL-2 alone). Our
analysis showed that CIK cell therapy was associated
with significantly prolonged one-year and two-year sur-
vival, OS and PFS, but had no effect on half-year survi-
val (p = 0.45). A favored DCR and ORR were also
observed in patients receiving CIK cell therapy (p <
0.01). The mechanism of anti-tumor activity of CIK cells
is still unclear. Schmidt-Wolf et al. [31] demonstrated
that perforin-mediated pathways possibly play an impor-
tant role in CIK cells induced tumor cell killing effect.
The study also indicated that patients receiving CIK
cell therapy had improved QoL compared with patients
in the non-CIK group (p < 0.01). Although CIK group
was associated with more fevers (p = 0.01). However,
fever after CIK cell transfusion was light in most trials
and lasted only 24 hours or less. In biological treat-
ments, moderate fever is considered to be a normal
reaction of immune function and beneficial to treatment
[32].
We also observed that the HBV-DNA and AFP levels
decreased significantly in the CIK group (p < 0.01).
Hepatitis B virus infection can lead to hepatic sclerosis
and HCC. AFP is currently widely recognized as a
tumor-related prognosis antigen for HCC. HCC patients
with high levels of HBV-DNA and AFP have a poor
prognosis [33,34]. Concomitant infection with HBV and
impairment from hepatic sclerosis in the hepatic par-
enchyma lead to an increase of AFP levels [35,36]. The
reduction of AFP content and HBV-DNA content con-
tribute to preventing the short-term recurrence of HCC
and prolonging patients’ survival time.
Targeting of the human immune system against tumor
mainly depends on cellular immunity. CD4+ T cells are
considered to have a predefined role as a helper T cell
within the immune system, providing help in recruiting
CD8+ T cells and activating macrophages through IFN-g
production. It has been demonstrated that cytotoxicity
against tumor is dependent on an appropriate CD4+ and
CD8+ T cell interaction. The ratios of T lymphocyte
subsets in peripheral blood are usually disordered in
tumor patients [37,38]. The analysis showed the percen-
tage of CD3+, CD4+ and CD3+CD4+ T cells significantly
increased in the CIK group, compared with the non-
CIK group, but the percentage of CD8+ and CD3+CD8+
T cells significantly decreased in the CIK group,
Figure 3 Comparison of 0.5-year, 1-year PFS between non-CIK group and CIK group. OR, odds ratio; PFS, progression-free survival; non-CIK,
non-CIK-based therapy; CIK, CIK-based therapy. The fixed effects model (Mantel-Haenszel method) was used in this analysis.
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compared with non-CIK group (p < 0.001). The percen-
tage of CD4+ T cells significantly increased, CD8+ T
cells significantly decreased, and thus the ratio of CD4
+/CD8+ increased. Therefore, immune suppression was
attenuated, enhancing the immune system’s tumor clear-
ance ability.
In present study, CIK cells were cultured in complete
medium (CM) supplemented with human blood serum in
eleven trials, and other two trials used serum-free medium
(SFM) to culture CIK cells. Mitomycin, cisplatin, anthracy-
cline and lipiodol were used for TACE. Most studies
showed that the culture of CIK cells amplified more and
produced more IFN-g, IL-4, or IL-5 in CM than in SFM
[39,40]. Our analysis showed that half-year PFS, one-year
PFS, one-year survival in the CM were 93.6%, 85.3%, 84.2%
which differ significantly from the 72.2%, 40.3%, 72.2% in
CIK cells cultured in the SFM. However, half-year survival
(68.5%) and two-year survival in the CM (51.5%) were
lower than those in SFM group (90.3%, 72.2%).
The present meta-analysis was not based on individual
patient data and was not subjected to an open external
evaluation procedure. Therefore, the analysis is limited
in that the use of published data may have led to an
over-estimation of the treatment effects. With respect to
both response and survival, we could not limit our ana-
lysis to intention-to-treat populations as the total num-
ber of patients randomized per arm was not always
reported. Therefore, for consistency among studies, we
elected to use the assessable patients for our analysis.
Moreover, all the selected trials in present study were
conducted in Asia, lacking multinational larger sample
multicenter clinic research with sufficient statistical
power. In order to solve this problem, a larger scale
international multicenter randomized clinical trial
should be conducted in the near future.
Figure 4 Forest plot for ORR and DCR. non-CIK, non-CIK-based therapy; CIK, CIK-based therapy; DCR, disease control rate; ORR, overall
response rate. The fixed effects meta-analysis model (Mantel-Haenszel method) was used in the analysis.
Table 2 Fever, improvement of QoL and HBV-DNA in
trials included in the analysis





Fever 0 12.40% 0.07 0.01 - 0.53 0.010
QOL improvement 58.54% 76.83% 0.32 0.16 - 0.64 0.001
QOL stability 31.70% 19.51% 2.52 1.22 - 5.20 0.010
QOL deterioration 9.76% 3.66% 2.91 0.79 -
10.64
0.110
HBV-DNA (> 1 × 103
copy/ml)




Summary differences of fever, improvement of QoL and HBV-DNA were
calculated using the random-effects model.
Note: QoL quality of life; HBV-DNA Hepatitis B virus DNA; pts patients; CIK CIK-
containing therapy; OR odds ratio; CI confidence interval.
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Taken together, the CIK cells were prepared after in
vitro priming and were transfused into patients with
HCC. These early results appear very promising, and
the side effects related to CIK cell transfusion were few.
It will hopefully lead to more large and controlled clini-
cal trials in these settings.
Conclusion
CIK cell therapy demonstrated a significant superiority
in prolonging the OS, PFS, DCR, ORR and QoL of HCC
patients compared with non-CIK therapy. These obser-
vations support further larger scale RCTs to evaluate
the efficacy of CIK cell therapy in the treatment of HCC
with or without the combination of other therapeutic
methods.
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